The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care
Open accessAbstract
It is almost ten years since the Banerjee 2009 report established that inappropriate prescribing of antipsychotics in the elderly was occurring in the UK and such patients had an 85% increased risk of adverse events and greater mortality. This report was a critical analysis addressing the outcomes of treatment practices for dementia in UK patients and globally, aimed at reducing prescribing of antipsychotic drugs for dementia. Since 2009, many significant studies worldwide (including several more recent large retrospective studies) provide more extensive longitudinal data for the adverse impacts of antipsychotic drugs in dementia. We have used the data in these studies including from over 380,000 dementia patients, with 85,069 prescribed antipsychotic agents as well as from 359,235 non-dementia antipsychotic drug users to provide an up-dated meta-analysis. This is the first meta-analysis to include evidence from general mental health studies showing that antipsychotic drugs precipitate excessive mortality across the spectrum. Prescribing of antipsychotic drugs for dementia or for other mental health care should be avoided and alternative means sought for handling behavioral disorders of such patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Research has shown that antipsychotics are associated with an increased risk of stroke and death in individuals with dementia.56,57”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [56]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“About one‐quarter of people with dementia have problems sleeping, and the problems can worsen as the disease progresses.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [68]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Hunter, J., & Schmidt, F. (2004) · doi:10.4135/9781412985031 · Cited by 3,023
Fixed-and random-effects models in meta-analysis.
Hedges, L. V., & Vevea, J. L. (1998) · Psychological Methods · doi:10.1037/1082-989x.3.4.486 · Cited by 2,977 · cited 3×
“In addition, the Hedges and Vevea [31] as well as the Hunter and Schmidt [30] methods for calculating the pooled estimate from the 20 studies were compared, giving similar point effect sizes for the pooled HR, 2.”
MethodInfluentialPeters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R., & Rushton, L. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.010 · Cited by 2,053
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa‐Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., et al. (2017) · World Psychiatry · doi:10.1002/wps.20420 · Cited by 1,729
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 2×
“In 2005, based on the published greater risk of cerebrovascular events (with risperidone, olanzapine, and aripiprazole) from meta-analysis of 17 randomized placebo controlled trials, the Federal Food and Drug Administration (FDA) in the USA noted that such atypical antipsychotics were associated with a 60–70% increase…”
BackgroundResultEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206 · cited 1×
“Worldwide, many similar studies over 2005–2009 were reported contraindicating use of antipsychotic drugs for dementia, with the majority clearly establishing and raising a serious red flag regarding their drug safety and adverse effects [9, 10, 12, 13, 20, 21].”
ResultAtypical antipsychotic drugs and the risk of sudden cardiac death
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194 · cited 7×
“This study compared those prescribed the atypical antipsychotics (risperidone (n = 4,406), olanzapine (n = 1,563), quetiapine (n = 497), and clozapine (n = 58) and 3,205 new users of conventional antipsychotics (haloperidol (n = 1,413), phenothiazines (including thioridazine [n = 546], perphenazine [n = 314], promazin…”
BackgroundResultInfluential
Research works printed but not linked: 1
- BanerjeeS (2009) The use of antipsychotic medication for people with dementia: Time for action. Department of Health UK Government, London.
Cited by
Items 101–163 of 163
Nuss, P., Corruble, E., Baloche, E., Garay, R. P., & Llorca, P. (2022) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2022.2108706 · Cited by 2
Han, J. H., Koch, E., Jeffery, A. D., Reese, T. J., Dorn, C. A., Pugh, S., Rubenstein, M. D., Wilson, J. E., Campbell, C., & Ward, M. J. (2023) · Academic Emergency Medicine · doi:10.1111/acem.14688 · Cited by 2
Detection of Alzheimer disease using deep learning
Rabeh, A. B., Miled, A. B., & Eid, A. I. A. (2023) · Journal Of Advanced Zoology · doi:10.53555/jaz.v44i5.3906 · Cited by 3
Malena, K., Rao, S., & Mosler, C. (2024) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2024.300 · Cited by 1
Tidmore, L. M., & Skrepnek, G. H. (2022) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000509 · Cited by 2
Pharmacotherapy of Alzheimer disease and neuropsychiatric symptoms of dementia
Prokopová, I. (2018) · Psychiatrie pro praxi · doi:10.36290/psy.2018.014 · Cited by 3
Halavonich, L., Robert, S., McGraw, D., Weeda, E. R., Mullinax, K., & Bass, B. (2020) · Mental Health Clinician · doi:10.9740/mhc.2020.01.025 · Cited by 2
“Days of inpatient antipsychotic therapy, median (IQR) 7 (2-13) 5 (1-12) .”
BackgroundAga, V. M., Shad, M. U., Zhu, H., & Salzman, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-800136-3.00023-5 · Cited by 3
Drugs for the Treatment of Alzheimer’s Disease
Seifert, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-18899-3_30 · Cited by 1
Neuropsychiatric disorders correction in Alzheimer's disease
Koberskaya, N. N. (2022) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2022-3-54-61 · Cited by 2
The ABCD approach for managing neuropsychiatric symptoms of dementia
Siple, A. (2023) · Nursing · doi:10.1097/01.nurse.0000942784.14340.1f · Cited by 1
Antipsychotics Use in the Elderly
Pustam, L., Weisse, A., & Bishnoi, R. J. (2024) · Advances in Psychiatry and Behavioral Health · doi:10.1016/j.ypsc.2024.05.012 · Cited by 2
Nagar, S., Ma, L., Pan, Y., Huynh, A. L. H., Tan, E. C. K., & Jin, L. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1425195 · Cited by 1
“For example, antipsychotics and benzodiazepines, are frequently prescribed and administered to manage behavioral and psychological symptoms of dementia (BPSD), despite limited efficacy and significant short-and long-term adverse effects, including death (11, 12).”
BackgroundArmstrong, M. J., Galvin, J. E., Manning, C. A., Boeve, B. F., Pontone, G. M., Taylor, A., Patel, B., Fleisher, J. E., & Maixner, S. M. (2025) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000660 · Cited by 1
Rao, S., McQuay, L. J., Forns, J., MacKay, R. E., Danysh, H. E., Doshi, D., Abler, V., Anthony, M. S., & Layton, J. B. (2025) · Drug Safety · doi:10.1007/s40264-025-01543-8 · Cited by 1
“Previous studies have suggested an increased risk in mortality among users of antipsychotics during the initial 180 days of use [21] and potential differences in mortality risk between users of pimavanserin and users of other antipsychotics (or untreated patients) in the first 30, 90, or 180 days…”
Culligan, J., Tasnim, N., Winter, P., Upthegrove, T., English, D. F., & Basso, J. C. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251334406 · Cited by 3
Neuropalliative Care in Dementia
Weisbrod, N. (2025) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/cont.0000000000001639 · Cited by 1
Pain as a cause of agitation in older subjects with cognitive impairment
Nowak, T. Ł., Neumann‐Podczaska, A., & Wieczorowska–Tobis, K. (2018) · Neuropsychiatria i Neuropsychologia · doi:10.5114/nan.2018.83036 · Cited by 2
Evidence database for deprescribing of antipsychotic drugs in elderly and senile patients
Tkacheva, O. N., Ostroumova, O. D., Сергеевич, К. Г., Isaev, R. I., & Kotovskaya, Y. V. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2019119051162 · Cited by 1
Pharmacotherapy of Alzheimer disease and neuropsychiatric symptoms of dementia
Prokopová, I. (2018) · Psychiatrie pro praxi · doi:10.36290/psy.2018.002 · Cited by 1
“Riziko zvýšené mortality se zdá být vyšší u antipsychotik první generace, typicky pro ha‐ loperidol (34).”
Luthra, A. S., Gao, R. L., Remers, S., Carducci, P., & Sue, J. L. (2022) · Geriatrics · doi:10.3390/geriatrics7010014 · Cited by 2
“The use of AAP in the management of Mis-identification Expressions (MiE) may be justified because of the specific psychological construct used to support the existence of this specific behavioral category, which is based on the impairment of information processing circuits, because of the dementia process [40].”
BackgroundMethodWichniak, A., Gustavsson, K., Wierzbicka, A., & Jernajczyk, W. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11322-4 · Cited by 1
The neuro-inflammasome in Alzheimer’s disease and cerebral strokePreprint
Lee, J. (2020) · doi:10.31219/osf.io/y2ugc · Cited by 1
Another Step Toward Clarifying the Benefits and Burdens of Selective Serotonin Reuptake Inhibitors
Wulsin, L. R. (2019) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000735
Effects of Antipsychotic Medication on Mortality in Long-Term Care Home Residents
Stones, M. J., Randle, J. M., & Brink, P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95388
Antipsychotic use in dementia – local quality improvement initiative
Waykar, V., Wourms, K., Bhat, G., & Farrow, A. (2021) · Progress in Neurology and Psychiatry · doi:10.1002/pnp.695
Dementia Management Act and Death Toll by Dementia DrugPreprint
Lee, J. (2021) · Research Square · doi:10.21203/rs.3.rs-384861/v2
Finnell, C. (2021) · KU ScholarWorks (The University of Kansas)
CBIAAT: Context Based Image Analyzer for Alzheimer’s Therapy
Kanthasamy, G., & Aponso, A. C. (2021) · Lecture notes in networks and systems · doi:10.1007/978-3-030-89880-9_14
Psychiatric aspects of care in the cancer patient
BREITBART, W. S., Alici, Y., & Kurzrok, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821976-8.00026-8
Dementia Management Act and Death Toll by Dementia DrugPreprint
Lee, J. (2021) · Research Square · doi:10.21203/rs.3.rs-384861/v1
Dementia Management Act and Death Toll by Dementia DrugPreprint
Lee, J. (2021) · Research Square · doi:10.21203/rs.3.rs-384861/v3
Rajagopalan, K., May, D., Worz, C., Hernandez, S. H., & Doshi, D. (2022) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2022.510
QUETIAPINE AND OLANZAPINE FOR TREATMENT OF PSYCHOSIS IN PEOPLE WITH VASCULAR DEMENTIA
KARIMOVA, R. Z. (2022) · EXPERIMENTAL & CLINICAL MEDICINE GEORGIA · doi:10.52340/jecm.2022.07.33
MANEJOS FARMACOLÓGICO E NÃO FARMACOLÓGICO EM IDOSOS COM DEMÊNCIA
Santos, A. C., Castro, O., de Sousa, L. T. V., Moura, Y. D. S., & de Galiza, F. T. (2022) · Instituto Produzir eBooks · doi:10.4322/978-65-84941-04-5-016
Demência em Idosos: abordagem interprofissional
(2022) · Instituto Produzir eBooks · doi:10.4322/978-65-84941-04-5
Dufour, I., Dubuc, N., Chouinard, M., & Hudon, C. (2022) · Geriatrics Gerontology and Aging · doi:10.53886/gga.e0220040
Rethinking Antipsychotics: Evidence-Based Medicine Calls for a Dramatic Change in Their Use
Whitaker, R. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-27003-1_3
COVID-19: A Worldwide Hecatomb in Long-Term Care Facilities
Predali, D. (2023) · Springer eBooks · doi:10.1007/978-981-99-1467-8_3
To the Editor and Readership of Alzheimer Disease and Associated Disorders
Tidmore, L. M., & Skrepnek, G. H. (2023) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000566
Mohr, P., Štuhec, M., & Bitter, I. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009067287.014
Kulkarni, R. R., Pai, R., Pandurangi, S. A., & Kalachari, M. B. (2024) · Annals of Indian Psychiatry · doi:10.4103/aip.aip_175_23
Suryadevara, U., Nuthi, M., Mihalik-Wenger, A. C., Hitching, R., & Fenn, H. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-53976-3_10
Aguilar-Navarro, S. G., Palacios-Hernández, M. G. I., Ouvrard, C., Gutiérrez-Gutiérrez, L., & Mimenza-Alvarado, A. J. (2024) · Salud Mental · doi:10.17711/sm.0185-3325.2024.028
“In particular, antipsychotics are associated with an increased risk of stroke and death (Ralph & Espinet, 2018).”
Mortality of alzheimer’s disease in Italy from 1980 to 2015
Bezzini, D., Smeralda, C. L., Pasqualetti, P., Cappa, S. F., Kundisova, L., Rossi, S., & Ulivelli, M. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07791-3 · Cited by 3
“…symptoms (irritability, agitation, sleep disturbances, delusions, hallucinations, aggression and impulsivity) commonly accompany dementia [28 ] and are often treated with antipsychotics, that have been linked with an overall increase of all-cause [ 29 ] and stroke-specific mor - tality [28].”
BackgroundLee, D. H., Chang, C., Chen, Y., & Tai, T. (2025) · Formosan Journal of Musculoskeletal Disorders · doi:10.4103/fjmd.fjmd-d-25-00004
Jiang, C., Krivinko, J. M., Yu, Z., Sweet, R. A., Zeng, L., Wang, H., Ding, Y., Zeng, Z., Kofler, J., & Wang, L. (2025) · medRxiv · doi:10.1101/2025.11.13.25340096
Sečník, J., Eriksdotter, M., Xu, H., Annetorp, M., Rytarowski, A., Johnell, K., Hägg, S., & Religa, D. (2023) · Figshare · doi:10.6084/m9.figshare.22603766
Du, H., Wang, X.-J., 赖小星, Wang, W., & Huo, X. (2024) · Figshare · doi:10.6084/m9.figshare.26367947
Sečník, J., Eriksdotter, M., Xu, H., Annetorp, M., Rytarowski, A., Johnell, K., Hägg, S., & Religa, D. (2023) · Figshare · doi:10.6084/m9.figshare.22603772
Sečník, J., Eriksdotter, M., Xu, H., Annetorp, M., Rytarowski, A., Johnell, K., Hägg, S., & Religa, D. (2023) · Figshare · doi:10.6084/m9.figshare.22603769
Karimi-Dehkordi, M., Asaana, P., Wagg, A., Hanson, H. M., & Harasym, P. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-102751
Jiang, C., Krivinko, J. M., Yu, Z., Sweet, R. A., Zeng, L., Wang, H., Ding, Y., Zeng, Z., Kofler, J., & Wang, L. (2026) · CNS Drugs · doi:10.1007/s40263-026-01286-9 · Cited by 1
“Although concerns about antipsychotic safety in dementia have been widely studied, most existing research has focused on comparisons between antipsychotic use and placebo or nonuse [5, 6].”
How exercise improves Alzheimer's disease
Niu, Y.-M. (2023) · Integrate Medicine · doi:10.61958/imkk9385
Kristiansen, F. A., Stige, B., Helle-Valle, A., & Brean, A. (2026) · Nordic Journal of Music Therapy · doi:10.1080/08098131.2026.2677886
Trajectories of Medication Use Prior to Death in US Nursing Home Residents With Dementia
Bochanis, A., Rumbut, J., Alcusky, M. J., & Tjia, J. (2026) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2026.106330
Browne, B., Rogers, I., Ali, K., Tabet, N., & Ford, E. M. (2026) · PLoS ONE · doi:10.1371/journal.pone.0351331
Carabine, F., Hughes, C. M., & Barry, H. E. (2026) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2026.07.011
Assisted Living Communities and their Residents
Wang, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-32088-9_2
Golda, A., Rico, M. S., Ramsay-Hellawell, E., Fayad, M., Leleu, E., Limosin, F., Hoertel, N., Adès, J., Alezrah, C., Amado, I., et al. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117555
BindingDB Entry 50018428: Progress in mechanistically novel treatments for schizophrenia.
BindingDB (2024) · UC San Diego · doi:10.7270/q2fr01sz
Metadata
- Authors
- Ralph, S. J., & Espinet, A. J.
- Affiliations
- Griffith University (AU)
- Corresponding author
- Ralph, Stephen J.
- ORCID
- Ralph, Stephen J.
- Venue
- Journal of Alzheimer's Disease Reports
- Publisher
- SAGE Publications
- Published
- 2018-02-02
- Volume
- 2
- Issue
- 1
- Pages
- 1-26
- ISSN
- 2542-4823 (ISSN-L)
- PMC
- PMC6159703
- OpenAlex
- W2786890905
- Cited by
- 160
- References
- 93
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 21 · 2023: 21 · 2022: 35 · 2021: 26 · 2020: 17 · 2019: 10 · 2018: 6
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (unspecified)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Alzheimer s Disease Reports (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Griffith Research Online (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- antipsychotic drugs, all-cause mortality, dementia, inappropriate prescribing, elderly patients, behavioral and psychological symptoms of dementia, adverse drug reactions, prescribing patterns
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.